Sarepta Therapeutics Inc. Common Stock (DE) (SRPT)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with durable earning power. Sarepta is a commercial-stage rare-disease biotech selling RNA-targeted and gene therapies, so it has real products and a $1.9B revenue base in FY2025, up from $1.8B in FY2024 and $1.1B in FY2023. But profits are wildly uneven. FY2023 net loss was $536.0M, FY2024 net income was $235.2M, and FY2025 net loss was $713.4M. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was $331.0M, but fiscal Q2 2026, the quarter ended 2026-06-30, showed a $4.9M loss. That is why FairStock calls it a TURNAROUND—loss in the latest year after earlier profits. The balance sheet offers some support: debt-to-equity is 0.70, and at the 2026-10-13 close FairStock calculates P/B of 1.14 and P/E of -10.52. Trailing free cash flow is $75.0M, a 4.3% FCF yield. Yet the quality scores are poor: ROE -9.48%, ROCE -1.13%, Piotroski 2/9, Altman Z -0.54, and FairStock Score 36/100. Rare-disease therapies can have pricing and regulatory barriers, but I see no clear margin of safety when losses are recurring and pipeline outcomes are binary. The stock is statistically cheap on book value, but cheapness without stable earning power is not enough. I would want to see sustained revenue, positive net income, and stronger cash generation before trusting the turnaround.

In plain English: Sarepta Therapeutics is a healthcare company that makes and develops medicines for rare genetic diseases, including Duchenne muscular dystrophy. The business has meaningful sales, but it is losing money again after a profitable year, and its financial safety signs look weak. At $16.51 on 2026-10-13, the shares trade below what its books say the company is worth, yet the uneven profits and losses make the price look more like a risky turnaround than a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer